Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancreatic cancer

Gómez-España, 2021, SEOM clinical guidelines for pancreatic and biliary tract cancer (2020), Clin Transl Oncol, 23, 988, 10.1007/s12094-021-02573-1 2022 Versteijne, 2018, Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer, Br J Surg, 105, 946, 10.1002/bjs.10870 Nimura, 2012, Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial, J. Hepatobiliary Pancreat Sci., 19, 230, 10.1007/s00534-011-0466-6 Okusaka, 2023, Clinical practice guidelines for pancreatic cancer 2022 from the Japan pancreas society: a synopsis, Int J Clin Oncol, 10.1007/s10147-023-02317-x Yamaguchi, 2022, Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01), Ann Surg, 275, 1043, 10.1097/SLA.0000000000005430 Okano, 2023, A prospective study of neoadjuvant gemcitabine plus nab-paclitaxel in patients with borderline-resectable pancreatic cancer, Intern Med, 62, 327, 10.2169/internalmedicine.9504-22 Miyasaka, 2019, Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates, Ann Surg Oncol, 26, 1528, 10.1245/s10434-019-07309-8 Yamashita, 2013, Tumor vessel depiction with contrast-enhanced endoscopic ultrasonography predicts efficacy of chemotherapy in pancreatic cancer, Pancreas, 42, 990, 10.1097/MPA.0b013e31827fe94c Emori, 2022, Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer, Pancreatology, 22, 525, 10.1016/j.pan.2022.04.005 Zhou, 2021, Correlation between enhancement patterns on transabdominal ultrasound and survival for pancreatic ductal adenocarcinoma, Cancer Manag Res, 13, 6823, 10.2147/CMAR.S307079 2015 Omoto, 2022, Tissue harmonic versus contrast-enhanced harmonic endoscopic ultrasonography for the diagnosis of pancreatic tumors: prospective multicenter study, Dig Endosc, 34, 198, 10.1111/den.13944 Kitano, 2012, Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography, Am J Gastroenterol, 107, 303, 10.1038/ajg.2011.354 Dietrich, 2008, Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound, J Cancer Res Clin Oncol, 13, 635, 10.1007/s00432-007-0326-6 Yamashita, 2015, Contrast-enhanced endoscopic ultrasonography for pancreatic tumors, BioMed Res Int, 2015, 10.1155/2015/491782 Liu, 2021, Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts, Adv Drug Deliv Rev, 172, 37, 10.1016/j.addr.2021.02.012 Lu, 2021, Nanomedicine strategies to enhance tumor drug penetration in pancreatic cancer, Int J Nanomed, 16, 6313, 10.2147/IJN.S279192 Damm, 2021, Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-A systematic review and meta-analysis, Cancers, 13, 4326, 10.3390/cancers13174326 Yamaguchi, 2022, Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01), Ann Surg, 275, 1043, 10.1097/SLA.0000000000005430 Ushida, 2021, High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment, Pancreatology, 21, 130, 10.1016/j.pan.2020.11.026 Rose, 2020, Sustained carbohydrate antigen 19-9 response to neoadjuvant chemotherapy in borderline resectable pancreatic cancer predicts progression and survival, Oncol, 25, 859, 10.1634/theoncologist.2019-0878 Xu, 2021, Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study, Gland Surg, 10, 770, 10.21037/gs-20-877 Unno, 2019, (Prep-02/JSAP-05), J Clin Oncol, 37